Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genetic risk model to predict outcomes for AML treated with HMA and venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRafeh SafdarJHJonah HeidelYAYanal Alnimer

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows genetic risk model predicts survival in AML patients treated with hypomethylating agents and venetoclax, indicating personalized treatment strategies are needed.

Key Points

  • Survival outcomes were significantly influenced by genetic profiles in AML patients treated with HMAs and venetoclax.
  • The genetic risk model effectively categorized patients into low-risk, intermediate-risk, and high-risk groups for overall survival.
  • NPM1 and IDH2 mutations were associated with improved survival, while TP53 mutation correlated with adverse outcomes.
  • Overall survival at 5.9 months for high-risk patients contrasted with 19.2 months in the low-risk group, highlighting prognostic value.

Cite This Study

Safdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d359https://doi.org/10.1182/blood-2025-1708
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  2. 2Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study2025
  3. 3Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study2025
  4. 4Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine2025 · 1 citations
  5. 5Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax2025